Sihuan Pharmaceutical Holdings Group Ltd. (HKG:0460)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 6.66B -56.3% |
| Revenue (ttm) | 3.04B +25.5% |
| Net Income | 348.42M |
| EPS | 0.04 |
| Shares Out | 9.00B |
| PE Ratio | 19.18 |
| Forward PE | 7.92 |
| Dividend | 0.01 (1.41%) |
| Ex-Dividend Date | Jun 30, 2026 |
| Volume | 18,985,000 |
| Open | 0.7400 |
| Previous Close | 0.7400 |
| Day's Range | 0.7100 - 0.7400 |
| 52-Week Range | 0.7100 - 1.9200 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About HKG:0460
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invas... [Read more]
News
Sihuan Pharmaceutical Holdings Group Earnings release: H1 2026
Sihuan Pharmaceutical Holdings Group released its H1 2026 earnings on August 26, 2026, summarizing the period's financial results.
Sihuan Pharmaceutical Holdings Group Slides: H1 2026
Sihuan Pharmaceutical Holdings Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 26, 2026.
Sihuan Pharmaceutical Holdings Group Annual report: H2 2025
Sihuan Pharmaceutical Holdings Group has published its H2 2025 annual report on March 31, 2026.
Sihuan Pharmaceutical Holdings Group Earnings release: H2 2025
Sihuan Pharmaceutical Holdings Group released its H2 2025 earnings on March 31, 2026, summarizing the period's financial results.
Sihuan Pharmaceutical Holdings Group Slides: H2 2025
Sihuan Pharmaceutical Holdings Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 31, 2026.
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
HONG KONG , June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"),...